Resumen de: US2023090551A1

A composition for detecting SARS-CoV-2 is provided; moreover, a kit including the composition, the use of the kit, and a method for detecting SARS-CoV-2 are also provided.

Resumen de: US2023090517A1

A composite quaternary ammonium salt disinfectant includes a double long-chain quaternary ammonium salt, two single long-chain quaternary ammonium salts, a synergist isothiazolinone, a nonionic surfactant fatty alcohol polyvinyl ether, and water, wherein the double long-chain quaternary ammonium salt is dialkyl dimethyl ammonium chloride with dialkyl being two independent alkyl groups with a chain length of C8-C18, and the two single-chain quaternary ammonium salts are alkyl dimethyl benzyl ammonium chloride with an alkyl chain length of C8-C18 and alkyl dimethyl ethyl benzyl ammonium chloride with an alkyl chain length of C8-C18, respectively. The composite quaternary ammonium salt disinfectant has a synergistic effect among its components, which greatly improves the capacity of resisting interferences by hard water and organics; and can kill not only bacterial propagules, lipophilic viruses (enveloped viruses, such as novel coronavirus) and fungi, but also hydrophilic viruses (non-enveloped viruses).

Resumen de: US2023090502A1

The present invention is directed towards methods, compositions and kits for testing SARS-CO-V2 virus in a sample. The methods determine the presence of a viral 3CL protease by contacting the sample with a peptide compound capable of being cleaved by the protease to form peptide compound fragments. Detection of a peptide compound fragment confirms the presence of the virus.

Resumen de: WO2023044505A2

The present invention provides constructs of the parainfluenza virus type-5 (PIV5) virus expressing the SARS-CoV-2 envelope spike (S) and nucleocapsid (N) proteins of SARS-CoV-2 variants for use as safe, stable, efficacious, and cost-effective vaccines against COVID-19.

Resumen de: WO2023044494A2

Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and/or nasal administration of the pharmaceutical composition.

Resumen de: WO2023044397A1

This disclosure relates generally to human ACE2 polypeptides that exhibit enhanced binding to the S protein of SARS-CoV-2, or increased affinity, that can be used as therapeutic agents in combination with monoclonal antibodies for the prophylaxis (pre- or post-exposure prophylaxis), or treatment of COVID-19, or disease caused by any coronavirus that utilizes ACE2 as a cellular receptor.

Resumen de: WO2023044344A1

The disclosure provides an animal cell stably expressing a virus-like particle (VLP). The disclosure also provides a method for manufacturing a virus-like particle, a virus-like particle, a vaccine composition, a method for preventing viral infection, and a method for producing antibodies.

Resumen de: WO2023043540A1

A method for virus detection is disclosed, including introducing a biological media to an aptamer functionalized electrochemical sensor, generating an electrochemical signal from a. reaction between a virus and an aptamer, analyzing the electrochemical signal to determine presence of the virus, analyzing the electrochemical signal to determine a. quantity of the virus, and transmitting a presence of the virus and a quantity of the virus. A device for virus detection and method for fabricating a device for virus detection is also disclosed. The device for virus detection also includes an electrode, a functionalized aptamer anchored to the electrode, where an aptamer is functionalized such that it is specific to a virus, such as SARS-CoV-2 or an alternate virus or interest. The device for virus detection may be wearable.

Resumen de: WO2023043213A2

The present invention relates to an ACE2 ectodomain-redesigned ACE2 variant comprising: i) an ACE variant, lacking the enzymatic activity of ACE2, for capturing virions of Sars CoV-2 or variants thereof and ii) an ACE2 receptor, having the enzymatic activity of ACE2, for detecting virions of Sars CoV-2 or variants thereof, and a method for detecting virions of Sars CoV-2 or its variants by using same. Compared to conventional antigen and antibody diagnostic kits that detect past viral infections by using non-structural proteins of viruses and cannot distinguish past inactive viral infections from currently active viral infections, the present invention excludes causative substances that may come from past infection and inactive infection history in light of the feature wherein it detects virions of Sars CoV-2 or its variants that are currently active. In addition, in the present invention, the ACE2 variants were polymerized to increase the affinity for the virions by up to thousands of times, compared to the conventional ACE2, and the number of ACE2 molecules bound per virion was significantly increased to amplify the diagnostic signal.

Resumen de: WO2023043033A1

A portable sterilizer is disclosed. A portable sterilizer, according to the present invention, comprises: a housing which has a water tank formed therein, and has a nozzle capable of spraying sterilizing water in a mist state, the nozzle being formed on one side of the housing so as to be exposed to the outside; an ozone gas supply unit formed inside the housing and supplying ozone gas to the nozzle; a compressed air supply unit formed inside the housing and supplying compressed air to the nozzle; and a water supply unit formed inside the housing and supplying water in the water tank to the nozzle, wherein the ozone gas and the compressed air are supplied in the form of a mixed gas to the nozzle, water is directly supplied to the nozzle, and the mixed gas and water are finally mixed inside the nozzle and then sprayed as sterilizing water in a mist state. According to the present invention, by spraying sterilizing water containing ozone in a mist state, it is possible to quickly sterilize and disinfect surfaces, indoor objects, and large areas exposed to coronavirus (SARS-CoV-2).

Resumen de: WO2023042928A1

The present invention relates to an inhalable pharmaceutical composition comprising budesonide or formoterol for preventing or treating COVID-19, and the composition exhibits more superb inhibitory effects on the virus than remdesivir injections and ciclesonide inhalations, which are known as therapeutic agents for COVID-19.

Resumen de: WO2023042181A1

A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity.

Resumen de: WO2023040835A1

Provided are an alpaca-derived nanobody combined with a SARS-CoV-2 RBD or an antigen-binding fragment thereof, and an application thereof. The nanobody may effectively inhibit SARS-CoV-2 pseudovirus infections, and may be used for the prevention, treatment and/or detection of SARS-CoV-2 infection.

Resumen de: WO2023040834A1

Provided are an alpaca-derived nanobody that binds to SARS-CoV-2 RBD and the use thereof. The nanobody can effectively inhibit infection with the SARS-CoV-2 pseudovirus, and can be used for preventing, treating and/or detecting SARS-CoV-2 infections.

Resumen de: WO2023042235A1

The present invention relates to antibodies against SARS-CoV-2 and uses thereof in the medical field for the prevention and treatment of SARS-CoV-2 infection and COVID-19 disease.

Resumen de: EP4151730A1

The present invention relates to specific reverse micelle system of the invention which allows the administration and intracellular delivery of unmodified oligonucleotide, such as siRNA, targeting one or more genes of the SARS-CoV-2 virus. The reverse micelle system of the invention is thus particularly useful for the treatment of COVID-19.

Resumen de: WO2021231651A2

Antibodies, including single-domain antibodies, that bind to SARS-CoV2 virus and methods of treatment using single-domain antibodies that bind to SARS-CoV2 virus are provided.

Resumen de: WO2021229519A1

The present invention relates to sterols for use in the prevention and/or in the treatment of a viral infection caused by SARS-CoV-2 (COVID-19).

Resumen de: WO2021229430A1

The present invention describes a novel process for the production of lysozyme HCl from hen egg white (HEW) with high chemical purity, and the use of said antiviral agent against SARS-CoV-2, optionally combined with other antivirals and/or immunosuppressants and ovotransferrin.

Resumen de: WO2021229450A1

RNA replicons encoding coronavirus S proteins, in particular SARS-CoV-2 S proteins, are described. Also described are pharmaceutical compositions and uses of the RNA replicons.

Resumen de: WO2021228750A1

The present invention relates to the use of organic and highly water-soluble compatible solutes or of a solute mixture, preferably in the form of an inhalable composition suitable for oropharyngeal, nasal and intravenous administration, in the prevention or treatment of diseases caused by ss(+)RNA viruses of the Coronaviridae family, preferably diseases caused by SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-HKU1, HCoV-OC43, HCoV-NL63 and/or HCoV-229E. Particularly suitable solutes according to the invention are ectoine and its derivatives, glycoin, mannosylglycerate (firoin) and mannosylglyceramide (firoin-A), which, by virtue of their strong water-binding capacity, reduce the binding of the viruses to the receptors of the host cell in the transitional epithelium, e.g. eye, in the inner epithelium, e.g. lung, and in the endothelium and thus reduce or prevent the reproduction of the virus. According to the invention, prevention is made possible by sputum and breath which are less infectious, and treatment and rehabilitation of the affected tissues are made possible by the membrane-protecting properties of the compatible solutes according to the invention.

Resumen de: WO2021228853A1

The present invention relates to a vaccine composition and its use against a Severe acute respiratory syndrome-related coronavirus.

Resumen de: WO2021231044A1

According to various embodiments, a machine-learning based system for coronavirus detection is disclosed. The system includes one or more processors configured to interact with a plurality of wearable medical sensors (WMSs). The processors are configured to receive physiological data from the WMSs and questionnaire data from a user interface. The processors are further configured to train at least one neural network based on raw physiological data and questionnaire data augmented with synthetic data and subjected to a grow-and-prune paradigm to generate at least one coronavirus inference model. The processors are also configured to output a coronavirus-based decision by inputting the received physiological data and questionnaire data into the generated coronavirus inference model.

Resumen de: WO2021231570A1

Provided herein are methods for the treatment and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.

Resumen de: WO2021231929A1

Present application relates to a strategy for compensating for transesterification degradation of lipid-encapsulated RNA, such as mRNA-LNP, in liquid formulations for high-volume distribution. This involves determining the rate of degradation of the encapsulated RNA and calculating an appropriate overage relative to the intended dose. Alternatively, a higher dose of the RNA may be administered to compensate for loss of effective RNA or the RNA may be formulated in higher purity in anticipation of degradation. The strategy provides a balance between supplying effective and safe products and the need for costly manufacturing processes or transportation hurdles, such as cold-chain supply.